BXQ-350 for Cancer

Phase-Based Progress Estimates
BXQ-350 - Drug
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial is for people who were already in other trials for BXQ-350. If they want, they can continue getting the treatment.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: From date of BXQ-350 treatment completion until time of death from any cause; up to approximately 5 years

Year 5
Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0
Percentage of subjects with clinical benefit
Year 5
Time to Disease Progression
Year 5
Overall Survival

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Continued Treatment
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: BXQ-350 · No Placebo Group · Phase 1

Continued Treatment
Experimental Group · 1 Intervention: BXQ-350 · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from date of bxq-350 treatment completion until time of death from any cause; up to approximately 5 years

Who is running the clinical trial?

CTI Clinical Trial and Consulting ServicesOTHER
31 Previous Clinical Trials
3,458 Total Patients Enrolled
Bexion Pharmaceuticals, Inc.Lead Sponsor
5 Previous Clinical Trials
332 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have completed the End of Study visit of the prior Bexion-sponsored BXQ-350 clinical study.
The investigator believes that continued treatment with BXQ-350 is clinically appropriate for the subject.
You have completed the required study observation period or time of closure for a prior BXQ-350 clinical study.
You are a female of child bearing potential (FCBP) and you have a negative serum pregnancy test result within 28 days prior to the first continuing treatment assessment for females of child bearing potential (FCBP).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 23rd, 2021

Last Reviewed: October 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.